ArticleBiomolecules2026
Phosphatidylserine Decarboxylase Regulates Retinal Ganglion Cell Neurite Outgrowth with Altered Somal Membrane Fluidics and Mitochondrial Morphology.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Mitochondrial lipid metabolism is an emerging regulator of neuronal regeneration, yet its role remains poorly defined. We investigated the function of phosphatidylserine decarboxylase (PSD), a mitochondrial enzyme that converts phosphatidylserine to phosphatidylethanolamine (PE), in retinal ganglion cell (RGC) regeneration. Using human glaucomatous degenerating optic nerves, we found PE was aberrantly accumulated with an elevated PSD expression and activity. In contrast, transcriptomes of regenerating RGCs present downregulated PSD, implicating PSD as a potential negative regulator of axonal growth. Using AAV2-mediated gene modulation, we evaluated how PSD knockdown (PSDKD) and PSD overexpression (PSDOE) alter RGC neurite outgrowth in vitro while evaluating effects on mitochondrial morphology, membrane fluidity by C-Laurdan staining, and lipidomes by LC-MS analysis. PSDOE did not support RGC neurite outgrowth, fragmented mitochondria, and increased polyunsaturated triacylglycerols. PSDKD significantly enhanced RGC neurite outgrowth and increased somal membrane fluidity accompanied by decreased cholesterol and saturated triacylglycerols. Notably, Doxorubicin, which attenuates PSD activity, increased neurite growth in PSDOE RGCs, supporting PSD's activity as a negative role for growth. Using the optic nerve crush degenerative model in C57BL/6 mice, we confirm PSDKD RGCs have higher growth competency in vivo. These findings indicate PSDKD positions RGCs in a more growth-permissive state.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.